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Protective Effect of Human Endogenous Retrovirus K
dUTPase Variants on Psoriasis Susceptibility
Olivia Y. Lai1,9, Haoyan Chen1,9, Henri-Alexandre Michaud2, Genki Hayashi1, Peter J. Kuebler2,
Gustaf K. Hultman2, Maria-Eugenia Ariza3,4, Marshall V. Williams3,4,5, Mariana D. Batista2,6,
Douglas F. Nixon2, John Foerster7, Anne M. Bowcock8 and Wilson Liao1
Previous genetic and functional studies have implicated the human endogenous retrovirus K (HERV-K) dUTPase
located within the PSORS1 locus in the major histocompatibility complex region as a candidate psoriasis gene.
Here, we describe a variant discovery and case–control association study of HERV-K dUTPase variants in 708
psoriasis cases and 349 healthy controls. Five common HERV-K dUTPase variants were found to be highly
associated with psoriasis, with the strongest association occurring at the missense single-nucleotide
polymorphism (SNP) rs3134774 (K158R, P¼ 3.28 1015, odds ratio ¼ 2.36 (95% confidence interval: 1.91–2.92)).
After adjusting the association of the HERV-K dUTPase variants for the potential confounding effects of HLA
alleles associated with psoriasis, the HERV-K SNPs rs9264082 and rs3134774 remained significantly associated.
Haplotype analysis revealed that HERV-K haplotypes containing the non-risk alleles for rs3134774 and rs9264082
significantly reduced the risk of psoriasis. Functional testing showed higher antibody responses against
recombinant HERV-K dUTPase in psoriasis patients compared with controls (Po0.05), as well as higher T-cell
responses against a single HERV-K dUTPase peptide (Po0.05). Our data support an independent role for the
HERV-K dUTPase on psoriasis susceptibility, and suggest the need for additional studies to clarify the role of this
dUTPase in the pathogenesis of psoriasis.
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INTRODUCTION
Psoriasis is an inflammatory, immune-mediated disorder of
the skin, joints, and nails that affects B3% of the US popu-
lation (Kurd and Gelfand, 2009). Significant morbidity is
associated with psoriasis because of its chronic, debilitating
nature and its established link to other systemic inflammatory
diseases (Kim et al., 2010). Although the risk of developing
psoriasis is known to be influenced by multiple genetic loci,
the strongest genetic effect appears to reside within the major
histocompatibility complex region on chromosome 6, a locus
known as PSORS1. Historical efforts to fine map the causative
variant(s) within PSORS1 were made difficult because of
the extensive linkage disequilibrium (LD) within the region.
Several studies localized PSORS1 to an B300-kb region
between HLA-B and HCG22, with varying boundaries identi-
fied between studies (Oka et al., 1999; Veal et al., 2002;
Lench et al., 2005; Martinez-Borra et al., 2005; Orru et al.,
2005; Nair et al., 2006; Fan et al., 2008). From this region,
the HLA-C*06:02 allele has been identified as the variant
most strongly associated with psoriasis (Nair et al., 2006).
Other HLA alleles that have been associated with psoriasis
or psoriatic arthritis are HLA-C*12, B*27, B*38, B*39, B*40,
and B*57 (Helms et al., 2005; Feng et al., 2009; Rahman
et al., 2011). Whether additional non-HLA variants within
PSORS1 may contribute to psoriasis susceptibility is still
unclear.
We were interested in exploring whether the PSORS1
human endogenous retrovirus K (HERV-K) dUTPase, located
32-kb telomeric of HLA-C (Figure 1), might be independently
associated with psoriasis. A previous analysis of several
hundred psoriasis families identified a strong psoriasis risk
haplotype, termed RH1, which localized to a 60-kb region
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telomeric to HLA-C (Nair et al., 2000) and which harbors the
HERV-K dUTPase. A subsequent analysis of the same data set
using a haplotype-sharing statistic demonstrated that the
HERV-K dUTPase may be a candidate susceptibility gene
for psoriasis (Foerster et al., 2005). Most recently, HERV-K
dUTPase protein has been shown to stimulate the production
of psoriasis-associated Th1/Th17 cytokines in immune cells
through interaction with Toll-like receptor 2 (Ariza and
Williams, 2011).
Human endogenous retroviruses (HERVs) are retroviruses
that have historically infected human populations and have
permanently integrated into the human genome via the
infection of germline cells. These retroviral sequences are
thereafter vertically transmitted from generation to genera-
tion. Although most HERV sequences have become defunct
through the accumulation of mutations, HERV sequences
possessing an intact open reading frame can lead to the
transcription and translation of viral proteins. The HERV-K
family of HERVs represents the historically most recent
addition to the human genome, and many HERV-K proviruses
contain intact open reading frames (Turner et al., 2001). The
HERV-K dUTPase at PSORS1 occurs within an open reading
frame, and messenger RNA transcripts of the dUTPase are
detectable in the skin and peripheral blood mononuclear
cells (PBMCs) of both psoriasis patients and healthy controls
(Foerster et al., 2005).
HERVs, which constitute a large portion (B8%) of the
human genome (Lander et al., 2001), have been implicated in
the development of psoriasis and several other autoimmune
diseases, although no definitive relationship has been demon-
strated. Retroviral-like particles have been detected in the
urine and skin of psoriasis patients (Dalen et al., 1983; Iversen,
1983), and overexpression of HERV-E envelope glycoprotein
(Bessis et al., 2004) and HERV-W RNA transcripts (Moles
et al., 2005) was found in psoriatic skin lesions compared
with control skin. HERVs have also been associated with
autoimmune conditions such as rheumatoid arthritis, sys-
temic lupus erythematosus, Sjogren’s syndrome, alopecia
areata, scleroderma, and multiple sclerosis (Banki et al.,
1992; Urnovitz and Murphy, 1996; La Placa et al., 2004;
Moyes et al., 2005; Rebora, 2005; Reynier et al., 2009). The
proposed mechanisms by which HERVs may trigger auto-
immune diseases include HERV encoding of autoantigens,
molecular mimicry between HERV and other self antigens,
HERV superantigens, the insertion of HERV sequences near
immune genes affecting gene regulation, and the activation of
innate immunity through pattern recognition receptors.
Considering the genomic localization of the HERV-K dUTPase
adjacent to HLA-C within PSORS1 and the functional evi-
dence of the ability of the dUTPase to stimulate production of
inflammatory cytokines in immune cells, we here used a
case–control approach to investigate the hypothesis that the
HERV-K dUTPase may be associated with psoriasis indepen-
dent of known HLA-C and HLA-B associations. We also
examined whether psoriasis patients generate B-cell and
T-cell immune responses against HERV-K dUTPase recombi-
nant protein and peptides, respectively.
RESULTS
HERV-K dUTPase variants at PSORS1 are strongly associated
with psoriasis
We sequenced a 431-bp genomic fragment of the PSORS1
HERV-K dUTPase in 708 Caucasian psoriasis cases and 349
Caucasian controls. Previous sequencing of a larger 4.2-kb
region around the dUTPase showed that the 431-bp fragment
contained the variants associated with high-risk and low-risk
psoriasis haplotypes (Foerster et al., 2005). The 431-bp
fragment encompasses the C-terminal portion of the dUTPase
protein starting at consensus amino-acid 108 and includes
dUTPase domains 3, 4, and 5. We identified a total of 14
DNA variants, 9 of which were new and rare (minor allele
frequency o5%; Table 1). We then conducted association
testing of the identified HERV variants with psoriasis using
logistic regression, adjusting the results for potential popula-
tion stratification using a panel of 87 European ancestry
informative markers (AIMs). We found that all five common
(minor allele frequency45%) HERV-K dUTPase polymorph-
isms were highly associated with psoriasis (Po104, exceed-
ing the Bonferroni threshold of 0.05/14¼0.0036, Table 1).
The HERV-K single-nucleotide polymorphism (SNP) most
highly associated with psoriasis was rs3134774, an A/G
polymorphism corresponding to the non-synonymous change
K158R (P¼ 3.281015, odds ratio (OR)¼2.36). rs3134774
was in nearly perfect LD with the noncoding SNP rs3134775
(r2¼ 0.99 in our data set) and in high LD with the noncoding
SNP rs3132531 (r2¼ 0.83; Figure 2). The synonymous HERV-
K SNP rs9264082, which was in low LD with rs3134774
(r2¼ 0.16), was associated with psoriasis protection (P¼
1.68109, OR¼0.50), as was the non-synonymous SNP
rs114780460 (P¼2.98 105, OR¼ 0.59). Although none of
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Figure 1. Location of human endogenous retrovirus K (HERV-K) sequence adjacent to HLA-C within the major histocompatibility complex region on
chromosome 6. The PSORS1 susceptibility locus containing one or more psoriasis risk variants has been mapped in various studies to the region between HLA-B
and HCG22. Cen: centromeric; Tel: telomeric. Scale at bottom is the human reference sequence assembly GRCh37/hg19.
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the nine rare HERV-K variants (minor allele frequencyo5%)
demonstrated statistical association with psoriasis, as would
be expected from power limitations, we did note that rare
variant NOVEL8 encoding the non-synonymous change
D166G was seen in four psoriasis cases and in none of the
controls (Table 1).
We also imputed the HLA-C*06:02 genotypes of all cases
and controls using a set of four tag SNPs, and the accuracy
of the imputation was empirically validated (see Materials
and Methods). None of the HERV-K SNPs were as strongly
associated with psoriasis as HLA-C*06:02 (P¼1.39 1022,
OR¼4.45, Table 1). Indeed, stepwise conditioning of the
HLA-C*06:02 association signal on the top HERV-K SNP
rs3134774 followed by rs9264082 (the next most significant
HERV SNP after all HERV SNPs were conditioned on
rs3134774) resulted in a residual association signal for
C*06:02 of P¼ 2.171013, OR¼ 3.51. As HLA-C*06:02
demonstrates the strongest overall association signal with
psoriasis and its association cannot be fully explained by the
effects of the HERV SNPs, we conclude that HLA-C*06:02 is
still the most significant risk factor for psoriasis at PSORS1.
HERV-K dUTPase SNPs are associated with psoriasis protection
independently of known HLA alleles
To evaluate whether the HERV associations with psoriasis
were independent of HLA alleles previously reported to be
associated with psoriasis or psoriatic arthritis (HLA-C*06,
C*12, B*27, B*38, B*39, B*40, and B*57; Helms et al., 2005;
Feng et al., 2009; Rahman et al., 2011), we first examined the
LD pattern between the HERV SNPs and these HLA alleles in
a subset of our psoriasis cases (n¼256) for which direct HLA
typing data were available. We found that C*06 and B*57
showed moderate LD with the HERV SNPs (max. r2¼0.46
and 0.19, respectively), and thus among HLA alleles had
the greatest likelihood of influencing HERV associations,
Table 1. Association testing of PSORS1 HERV-K dUTPase variants with psoriasis
SNP/variant
Chr 6 position
(hg19)
Major/minor
alleles
Amino-acid
change
MAF
cases
MAF
controls P-value
OR
(95% CI) P-valueadj
OR
(95% CI)adj
FDR
q-value
NOVEL1 31201267 A/T — 0.0007 0.0000 0.9993 — — — 1
NOVEL2 31201299 T/G — 0.0014 0.0000 0.999 — — — 1
rs3134775 31201357 T/G — 0.4595 0.2855 9.97E15 2.31 (1.872.86) 0.0037 1.43 (1.221.81) 0.0173
NOVEL3 31201357 T/C — 0.0000 0.0014 0.9993 — — — 1
NOVEL4 31201376 G/A — 0.0404 0.0390 0.8532 — — — 0.4000
NOVEL5 31201378 C/A — 0.0021 0.0042 0.4581 — — — 0.9454
NOVEL6 31201378 C/T — 0.0014 0.0000 0.9991 — — — 1
NOVEL7 31201438 G/A — 0.0000 0.0111 0.998 — — — 1
rs3132531 31201472 G/A — 0.4224 0.2535 3.48E14 2.31 (1.862.86) 0.0263 1.33 (1.031.71) 0.0921
NOVEL8 31201499 A/G D (166) G 0.0028 0.0000 0.9987 — — — 1
rs9264082 31201514 A/G L (161) L 0.1622 0.2779 1.68E09 0.50 (0.400.63) 2.50E04 0.64 (0.510.81) 0.0035
rs3134774 31201524 A/G K (158) R 0.4596 0.2827 3.28E15 2.36 (1.912.92) 0.0020 1.46 (1.151.85) 0.0140
rs114780460 31201534 G/A G (155) R 0.1199 0.1927 2.98E05 0.59 (0.460.76) 0.0511 0.78 (0.601.00) 0.1431
NOVEL9 31201541 G/A P (152) P 0.0000 0.0056 0.9986 — — — 1
HLA-C*06:02 — — — 0.2722 0.0879 1.39E22 4.45 (3.306.00) — — —
HLA-B*57:01 — — — 0.1412 0.0385 3.28E11 4.06 (2.686.15) — — —
Abbreviations: Chr, chromosome; CI, confidence interval; FDR, false discovery rate; HERV-K, human endogenous retrovirus K; MAF, minor allele frequency;
OR, odds ratio; SNP, single-nucleotide polymorphism.
P-values and ORs for association with psoriasis are shown before and after adjustment for HLA-C*06:02 and HLA-B*57:01 (rightmost columns). FDR
q-values for the conditional tests are shown.
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Figure 2. Linkage disequilibrium plot for HLA-C*06:02, HLA-B*57:01, and
HERV-K dUTPase single-nucleotide polymorphisms (SNPs). r2 Values
between pairs of SNPs are shown.
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whereas the other HLA alleles showed significantly lower LD
(all r2o0.09) and were not likely to influence HERV associa-
tions, despite some having high D0 values (see Supplementary
Table S1 online for full explanation). Therefore, in addition to
our imputed HLA-C*06:02 data, we also determined HLA-
B*57:01 in all cases and controls using the tag SNP
rs2395029, which is in very high LD (r2¼ 1.0) with HLA-
B*57:01 in Caucasians of European descent (de Bakker et al.,
2006). We conditioned the association signals of the five
significant HERV SNPs on HLA-C*06:02 and HLA-B*57:01
using logistic regression (Table 1, rightmost columns). We found
that several HERV-K SNPs showed independent associations
with psoriasis. The strongest independent effect was from
rs9264082 (P¼ 2.50104, OR¼0.64) followed by rs3134774/
rs3134775 (P¼ 0.0020, OR¼1.46 and P¼0.0037, OR¼1.43,
respectively). All three of these HERV SNPs remained significant
(qo0.05) after adjusting for multiple testing using the false
discovery rate method (Benjamini and Hochberg, 1995). A
trend toward independence was seen for rs3132531
(P¼ 0.026, OR¼ 1.33, q¼0.092) and rs114780460 (P¼ 0.051,
OR¼0.78, q¼ 0.143).
To further elucidate the relationship of the HERV-K
dUTPase SNPs with each other, we estimated the frequencies
of haplotypes containing rs114780460, rs3134774, and
rs9264082 and performed haplotype association testing,
adjusting for the effects of HLA-C*06:02 and HLA-B*57:01
(Table 2). We did not include rs3134775 or rs3132531 in the
haplotype analysis because of their high LD with rs3134774
(r2¼ 0.99 and r2¼ 0.83, respectively). We identified four
haplotypes, H1 to H4, which accounted for greater than
99.5% of the total number of haplotypes in both cases and
controls. We found that three haplotypes—H2, H3, and H4—
were independently associated with psoriasis protection.
All three haplotypes contained the non-risk allele A of
rs3134774, whereas the presence of the protective allele G of
rs9264082 in H3 and H4 further reduced psoriasis risk
compared with H2. Our haplotype data demonstrate that
haplotypes containing protective HERV alleles (allele A of
rs3134774 and allele G of rs9264082) can independently
reduce the risk for psoriasis.
Evaluation of B-cell immunity to HERV-K dUTPase protein
To determine whether HERV-K dUTPase protein elicits
humoral responses, we tested sera from 23 psoriasis patients
and 16 healthy donors for responses to recombinant wild-
type HERV-K dUTPase. As shown in Figure 3, psoriasis
subjects had a greater humoral response against HERV-K
dUTPase compared with the healthy blood donors (P¼0.0334,
Mann–Whitney U-test). No response was observed against
vehicle control or against human dUTPase control protein
even at the lowest dilution used (data not shown). Our data
suggest that certain epitopes in the HERV-K dUTPase protein
may be eliciting an immunological response in psoriasis
patients. Future studies examining the specificity of the
antibody response against the high-risk and low-risk dUTPase
proteins as defined by our genetic analysis are warranted.
Evaluation of T-cell immunity to HERV-K dUTPase peptides
To evaluate whether HERV-K dUTPase peptides might elicit
T-cell responses, we tested the PBMCs of 13 psoriasis patients
and 11 healthy controls for ELISPOT IFN-g responses to
peptides from the PSORS1 HERV-K dUTPase. Peptides were
designed as overlapping 13-mer sequences spanning the
Table 2. Association of 3-marker HERV-K haplotypes with psoriasis
Haplotype rs114780460 [AA 155] rs3134774 [AA 158] rs9264082 Case frequency Control frequency P-value OR (95% CI)
H1 G [G] G [R] A 0.4583 0.2848 — 1.00 (reference)
H2 G [G] A [K] A 0.3743 0.4322 0.0370 0.77 (0.600.99)
H3 A [R] A [K] G 0.1229 0.1955 9.43E04 0.59 (0.430.81)
H4 G [G] A [K] G 0.0422 0.0838 2.80E05 0.40 (0.260.61)
Abbreviations: CI, confidence interval; [G], glycine; HERV-K, human endogenous retrovirus K; [K], lysine; OR, odds ratio; [R], arginine.
For missense single-nucleotide polymorphisms (SNPs) rs114780460 and rs3134774, the corresponding amino acids at HERV-K dUTPase protein positions
155 and 158 are shown. Haplotype associations were adjusted for the effects of C*06:02 and B*57:01. Haplotypic ORs are expressed in reference to the
most frequent haplotype.
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Figure 3. IgG antibody responses against recombinant human endogenous
retrovirus K (HERV-K) dUTPase. The response against HERV-K dUTPase was
screened using 23 psoriasis patient serum samples and 16 healthy donor
serum samples at a 1:800 dilution. The human dUTPase was used as a
control. Psoriasis subjects had a greater humoral response against HERV-K
dUTPase compared with the healthy blood donors. No response against the
human dUTPase was detected even at the lowest dilution used (data not
shown). *Po0.05, Mann–Whitney U-test.
1836 Journal of Investigative Dermatology (2012), Volume 132
OY Lai et al.
Association of HERV-K dUTPase with Psoriasis
region from amino-acid 129 of the dUTPase (just beyond
conserved domain 3) to the carboxy terminus of the dUTPase
(Supplementary Figure S1 online). Peptides were designed to
contain either the wild-type dUTPase sequence or various
combinations of the amino-acid substitutions corresponding
to rs114780460, rs3134774, or variant NOVEL8 identified in
our study. Within the psoriasis samples, no overall differ-
ences were observed when comparing PBMC reactivity
against the psoriasis risk–associated peptides versus the pso-
riasis protection–associated peptides, with only one psoriasis
patient reacting against the risk-associated peptides (Supple-
mentary Table S2 online). However, interestingly, we identified
a HERV-K dUTPase peptide (PGECIAQLLIVPY) that elicited
reactivity in 5/13 (38.5%) of psoriasis patients versus 0/11
(0%) of controls (P¼ 0.0473, Mann–Whitney U-test; Supple-
mentary Table S2 online). Two of five responses were of
moderate strength, with spot-forming units per 106 4200.
This sequence appears to be specific for the PSORS1
dUTPase as it differs by four amino acids from the wild-type
HERV-K dUTPase sequence (PGDRIAQLLLLPY, differences
underlined), and protein BLAST alignment of PGECIAQLLIV-
PY against the human protein database did not reveal any
other identical matches. This sequence also contains a
number of potential epitopes based upon HLA allele motif
scanning, including peptides restricted through HLA-C*06:02.
Although requiring further investigation, this suggests the
possibility that immune reactivity against HERV-K dUTPase
peptides might be involved in the pathogenesis of psoriasis.
DISCUSSION
In this study, we took a candidate gene approach to evaluate
whether a HERV-K dUTPase sequence in the major histo-
compatibility complex region is associated with psoriasis. By
sequencing the dUTPase in 708 cases and 349 controls, we
found that HERV-K dUTPase variants at PSORS1 are strongly
associated with psoriasis but that this association was not as
strong as the association of psoriasis with HLA-C*06:02. To
determine whether dUTPase variants were associated with
psoriasis independent of psoriasis-associated HLA alleles, we
determined the LD between the HERV variants and these
HLA alleles and identified HLA-C*06:02 and HLA-B*57:01 as
the most likely potential confounders. We then performed
association testing of HERV variants conditional on HLA-
C*06:02 and HLA-B*57:01 and found that two variants within
the dUTPase, rs9264082 and rs3134774, remained indepen-
dently associated. The minor allele A of the missense SNP
rs114780460 was also protective against psoriasis (OR¼0.78),
but its effect was not quite independent (P¼ 0.051).
rs9264082 encodes the synonymous change L161L,
whereas rs114780460 and rs3134774 encode missense SNPs
corresponding to G155R and K158R substitutions, respec-
tively. Our haplotype analysis shows that the haplotype
155G/158R, previously termed ‘‘high-risk’’ (Foerster et al.,
2005), is the most common haplotype in psoriasis patients
(Table 2). Foerster et al.’s ‘‘low-risk’’ haplotype 155R/158K
corresponds to protective haplotype H3 in our analysis;
however, the haplotype 155G/158K, which was not reported
by Foerster et al., also corresponds to protective haplotypes
H2 and H4 (Table 2). Ariza and Williams (2011) studied
whether the 155G/158R substitutions and the 155R/158K
substitutions (the latter associated with psoriasis protection)
influenced the ability of recombinant HERV-K dUTPase
protein to stimulate cytokine responses when added to human
primary cells. In agreement with the genetic prediction from
our data, recombinant protein containing 155G/158R showed a
significantly increased ability to stimulate Th1 and Th17 cytokines
compared with protection-associated 155R/158K recombi-
nant protein in human primary dendritic cells. The authors
also tested the effects of the single substitutions 158R and
158K, which did not show the expected trend; however, in
these two cases, 158R and 158K were paired with 155K, a
situation that is never observed at the PSORS1 HERV-K
dUTPase in which amino-acid position 155 can only harbor a
G (glycine) or R (arginine). Indeed, it is important to note that
the recombinant protein experiments conducted by Ariza and
Williams used as their baseline protein the wild-type HERV-K
dUTPase sequence, which is present in many copies
throughout the human genome but which differs in sequence
slightly from the PSORS1 HERV-K dUTPase at the N terminus
and C terminus. Therefore, interpretation of the functional
effects of the G155R and K158R polymorphisms require
additional studies that examine these changes within the
context of the PSORS1 dUTPase specifically.
We tested whether psoriasis patients mounted humoral
responses against the HERV-K dUTPase protein. Using an
ELISA assay, we found higher antibody responses against
wild-type HERV-K dUTPase in psoriasis patients compared
with healthy controls. The response was specific for HERV-K
dUTPase, as human dUTPase did not elicit reactivity. Future
work is needed to define the relevant reactive epitopes and to
determine whether there is a differential antibody response to
dUTPase protein containing lysine at position 158, corre-
sponding to the protective genetic variant identified here. We
also tested whether HERV-K dUTPase peptides could elicit
immunological responses from PBMCs of psoriasis patients
and healthy controls. We found T-cell responsivity to several
of the peptides, with peptide P04 being recognized in 5/13
psoriasis patients, including 2 at moderate strength. This 13-
amino-acid sequence has several potential HLA anchor
motifs, including that of HLA-C*06:02, among others. The
fact that our screen did not detect a differential response
against the psoriasis-associated genetic variants does not rule
out a potential functional role for these variants. For effi-
ciency, we tested 13-mer peptides staggered by five amino
acids, but this does not cover all possible peptide sequences.
We also did not examine the possibility that skin-resident
immune cells might react to these peptides. In addition, it is
possible that these genetic variants might be important for the
secondary or tertiary structure of the dUTPase protein, which
could affect interaction with innate pattern receptors such as
TLR-2, a mechanism that is not addressed with peptide
experiments.
Apart from modulating immune response, endogenous
retroviral dUTPase may harbor alternative psoriasis-relevant
properties. Related dUTPases have been found to interact
with peroxisome proliferator–activated receptor isoforms
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(Chu et al., 1996) and human dUTPase specifically with
peroxisome proliferator–activated receptor delta (Rual et al.,
2005), previously implicated in psoriasis (Westergaard et al.,
2001; Romanowska et al., 2010). In addition, human
dUTPase was recently shown to function as an unconven-
tional high-affinity DNA-binding protein that interacts with
specific target sequences independently of enzymatic function
(Hu et al., 2009). It is quite possible that such functions are
retained in truncated homologous HERV-K dUTPase fragments.
In conclusion, using a large case–control cohort, we have
identified variants within the HERV-K dUTPase gene at
PSORS1, which have an effect on psoriasis susceptibility
independent of HLA loci known to be associated with
psoriasis. Our functional studies preliminarily suggest that
certain HERV-K dUTPase epitopes and peptides may elicit
immunological responses more frequently in psoriasis pa-
tients than in healthy controls. Given the extensive LD within
the major histocompatibility complex region, replication of
our genetic findings in additional cohorts is warranted and
further mapping studies are needed to evaluate the possibility
that the independent HERV variants identified here are
markers of other causal variants in the region. Nevertheless,
this study advances the evidence that the HERV-K dUTPase at
PSORS1 may be involved in the pathogenesis of psoriasis and
suggests the importance of additional genetic and immuno-
logical work to clarify the role of this dUTPase in psoriasis.
MATERIALS AND METHODS
Samples
DNA samples from 708 Caucasian psoriasis cases and 359
Caucasian healthy controls were collected from the University of
California, San Francisco and Washington University, St Louis.
Psoriasis cases included 50.4% women and had a mean age of onset
of 24.6 years (SD 15.5). Psoriasis serum and PBMC samples were
collected from the University of California, San Francisco, and
healthy control serum and PBMCs from volunteer donors at the
Blood Centers of the Pacific. All subjects provided written informed
consent for study participation under the approval of local
institutional review boards. This study adheres to the Declaration
of Helsinki Principles.
HERV-K sequencing and identification of variants
PCR was used to amplify a 431-bp segment of the HERV-K dUTPase
at PSORS1 for sequencing. SNPs within this amplicon have pre-
viously been shown to be associated with high-risk and low-risk
psoriasis haplotypes (Foerster et al., 2005). The forward primer used
was 50-AAGTTTAAAAGGCATACAAATACATACAGGG-30. The reverse
primer used was 50-GGACCTTCACAATGCAAAATATAATGG-30.
These primers are specific for the PSORS1 HERV-K dUTPase as
confirmed by BLAT analysis. The PCR conditions were as follows:
95 1C for 2 minutes; 35 cycles of 92 1C for 10 seconds, 58 1C for
20 seconds, 72 1C for 1 minute; hold at 4 1C. PCR products were
sequenced at a commercial facility (Quintara Biosciences,
Berkeley, CA) using an ABI 3730xl (Applied Biosystems, Carlsbad, CA).
Polymorphisms were identified through a visual examination of the
DNA sequencing chromatograms (Sequencher 4.0, Gene Codes, Ann
Arbor, MI). All detected variants were successfully sequenced in
greater than 95% of samples, and no variants had a Hardy–Weinberg
equilibrium P-valueo0.01. Amino-acid numbering for the dUTPase
protein was carried out in concordance with the previously
published report by Ariza and Williams (2011).
HLA-C*06:02 and HLA-B*57:01 genotype imputation and
validation
The HLA-C*06:02 genotypes for cases and controls were imputed
using a modification of de Bakker et al. (2006) based on a combina-
tion of four SNPs that were in LD with HLA-C*06:02. These four
SNPs were genotyped using a combination of TaqMan assays (rs2894207
and rs887466) and Illumina GoldenGate assays (rs1062470 and
rs10484554). The program SNPAnalyzer (Yoo et al., 2005) was used
to generate haplotypes from these SNPs. HLA-C*06:02 corresponds
to the haplotype CGTT for SNPs rs2894207, rs887466, rs1062470,
and rs10484554, respectively. HLA-B*5701 was determined by
genotyping all samples on the Illumina Goldengate platform for
rs2395029, a tag SNP in high LD (r2¼ 1.0) with HLA-B*57:01 (de
Bakker et al., 2006). The validity of the imputation for HLA-C*06:02
was confirmed by comparing the imputed genotypes with actual
genotypes that were known for a subset (n¼ 233) of samples based
on sequence-specific oligonucleotide probe HLA typing (Helms
et al., 2005). Overall, the imputation accuracy rate for HLA-C*06:02
was 98.7%.
Ancestry informative markers
To adjust for potential population stratification between cases and
controls, 98 European AIMs, which comprised a subset of the top
100 European AIMs reported by Price et al. (2008), were genotyped
in both cases and controls using the Illumina GoldenGate platform.
After removing AIMs witho95% genotyping in all samples, Illumina
GenTrain quality score o0.5, and Hardy–Weinberg equilibrium
P-valueo0.0001, 87 high-quality AIMs remained, which were used
in the subsequent analysis.
Association testing and statistical analysis
Additive logistic regression models in PLINK (Purcell et al., 2007)
were used for the association testing. To account for potential
population stratification or admixture in these samples, principal
component analyses were performed using EIGENSTRAT (Price
et al., 2006). Four principal components derived from 87 AIMs
were included as covariates in the logistic regression models.
Calculation and visualization of LD between HERV variants and
HLA alleles was performed in Haploview (Barrett et al., 2005).
False discovery rate q-values were calculated in R. Haplotype
frequency estimation, and haplotype association testing were
performed using THESIAS, which uses the stochastic E-M method
(Tregouet and Garelle, 2007).
HERV-K dUTPase ELISA assays
The 96-microtiter well plates (Nunc-Immuno Plate MaxiSorp Surface)
were coated overnight at 4 1C with the recombinant HERV-K
dUTPase or human dUTPase protein at 2.5mgml1 in phosphate-
buffered saline (PBS). Purification of recombinant dUTPase was
performed as previously described (Ariza and Williams, 2011).
Plates were then washed three times with 200ml of PBS/0.05%
Tween 20 and blocked with 100ml of blocking buffer (PBS/2.5%
BSA) at room temperature (RT). The samples were diluted in
blocking buffer and incubated for 2 hours at RT in duplicates. Plates
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were then washed three times with 200ml of PBS/0.05% Tween 20.
An antihuman-IgG HRP-conjugated secondary antibody was diluted
at 1:1,000 in blocking buffer and incubated at RT for 1 hour. Plates
were then washed six times with 200ml of PBS/0.05% Tween 20 and
incubated for 10 minutes with 100ml of tetramethylbenzidine
(Invitrogen, Carlsbad, CA). A volume of 50 ml H2SO4 (2M) was
added to stop the reaction. The plates were read at 450 and 690 nm
for the background on a plate reader. The background from the 690-
nm uncoated wells and PBS–BSA (negative controls) were subtracted
from the mean absorbance of the coated wells. A high responder
serum was used to normalize the results. Statistical analysis was
performed using a nonparametric Mann–Whitney test using Prism
5.0a from the GraphPad Software (GraphPad Software, La Jolla, CA).
A positive result was defined as a serum that led to a signal twice
over the background OD.
HERV-K dUTPase peptide ELISPOT assays
PBMCs were isolated from EDTA–anticoagulated blood, and
cryopreserved in liquid nitrogen until being thawed overnight before
the ELISPOT assay. ELISPOT IFN-g assays were carried out with
individual 13-mer peptides (Supplementary Figure S1 online).
Peptides were used at a final concentration of 10mgml1. Briefly,
96-well flat-bottomed nitrocellulose plates (Multiscreen, Millipore,
Bedford, MA) were quickly humidified with 1X PBS and then
coated with anti-IFN-g mAb (Mabtech, Nacka, Sweden) in 1X PBS
and incubated for 1 hour at RT. Plates were washed four times with
1X PBS and then incubated at 37 1C in 5% CO2 for 1 hour with
RPMI 1640 supplemented with penicillin, streptomycin, and 10%
fetal bovine serum (R10). One hundred thousand viable thawed
PBMCs in R10 were added to the wells. Phytohemagglutinin and a
peptide pool from cytomegalovirus, Epstein–Barr virus, and influenza
virus (CEF) were used as positive controls, and media only as a
negative control. Plates were incubated for 16–18 hours at 37 1C in
5% CO2, after which the cells were discarded. After washing the
plates twice with 1X PBS and twice with 1X PBST (1X PBS
containing 0.1% Tween 20), biotinylated anti-IFN-g mAb (Mabtech)
in 1X PBSTB (1X PBST containing 2% BSA) was added. Plates
were incubated for further 30 minutes at RT. After two additional
washes with 1X PBST, streptavidin–alkaline phosphatase conjugate
(Jackson ImmunoResearch, West Grove, PA) in 1X PBSTB was
added and incubated for 30 minutes to 1 hour at RT. Plates were
then soaked in 1X PBST for 30 minutes to 1 hour. Developer
solution (Vector Laboratories, Burlingame, CA) was added for about
15 minutes. Plates were rinsed with tap water and dried, and then
spots were counted using an AID reader (AID, Obenhochen,
Germany). HERV-K-specific responses were reported as the number
of spot-forming units per 1.0 106 PBMCs after subtraction of twice
the background IFN-g secretion.
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